Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.50 |
| ▸ | PRKDC | P78527 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 4/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 4/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 2/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1923471 | 0.87 | PIK3CD (0.48) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL1923294 | 0.86 | PIK3CD (0.64) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL1923556 | 0.79 | SRC (0.41) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL1923298 | 0.75 | PIK3CD (0.60) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL15613570 | 0.72 | PIK3CD (0.81) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL1923920 | 0.70 | PDE2A (0.37) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL1268719 | 0.69 | MAOB (0.81) | MAOBMEN1KMT2ACYP4F2CYP4A11 | |
| SCHEMBL1923530 | 0.69 | SRC (0.50) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL28182081 | 0.68 | MAOB (0.79) | MAOBMEN1KMT2ACYP4F2CYP4A11 | |
| SCHEMBL130425 | 0.67 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968554-B2 | Pyrazolo[3,4-d]pyrimidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968554-B2 | Pyrazolo[3,4-d]pyrimidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968554-B2 | Pyrazolo[3,4-d]pyrimidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-06-28 | — | — | US | disclosed |
| EP-2188290-B1 | PYRAZOLO[3,4-D]-PYRAMIDINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | HOFFMANN LA ROCHE (CH) | 2011-06-08 | — | — | EP | disclosed |
| EP-2188290-B1 | PYRAZOLO[3,4-D]-PYRAMIDINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | HOFFMANN LA ROCHE (CH) | 2011-06-08 | — | — | EP | disclosed |
| EP-2188290-A1 | PYRAZOLO[3,4-D]-PYRAMIDINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | F. Hoffmann-Roche AG (CH) | 2010-05-26 | — | — | EP | disclosed |
| US-20090048274-A1 | PYRAZOLO[3,4-d]PYRIMIDINE DERIVATIVES | BARTKOVITZ DAVID JOSEPH | 2009-02-19 | — | — | US | disclosed |
| US-20090048274-A1 | PYRAZOLO[3,4-d]PYRIMIDINE DERIVATIVES | BARTKOVITZ DAVID JOSEPH | 2009-02-19 | — | — | US | disclosed |
| US-20090048274-A1 | PYRAZOLO[3,4-d]PYRIMIDINE DERIVATIVES | BARTKOVITZ DAVID JOSEPH | 2009-02-19 | — | — | US | disclosed |
| WO-2009021869-A1 | PYRAZOLO[3,4-D]-PYRAMIDINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009021869-A1 | PYRAZOLO[3,4-D]-PYRAMIDINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048274-A1 | PYRAZOLO[3,4-d]PYRIMIDINE DERIVATIVES | BRAF, RAF1, PRKDC | PIK3CD 117/4885PIK3CA 67/4885PIK3CB 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.